Streetbeat News

COEP

Coeptis Therapeutics Holdings Inc

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

0.22

Mkt cap

8.3M

Volume

1.1M

High

0.22

P/E Ratio

-0.44

52-wk high

1.33

Low

0.18

Div yield

N/A

52-wk low

0.15

Coeptis Therapeutics has expanded its exclusive license agreement with the University of Pittsburgh to include autoimmune indications for its SNAP-CAR T and SNAP-CAR NK technology. This platform, which can target multiple antigens simultaneously, now extends its potential applications beyond oncology to various autoimmune diseases.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 2:02 pm

In Monday's after-market session, several healthcare stocks showed notable movements. BioSig Technologies, Coeptis Therapeutics, Alzamend Neuro, China Pharma Holding, AIM ImmunoTech, and Better Therapeutics were among the gainers, with increases ranging from 4.99% to 7.7%. On the downside, G1 Therapeutics, InVivo Therapeutics, 23andMe Holding, Calidi Biotherapeutics, Beyond Air, and Syra Health experienced declines between 6.61% and 37.5%. Notably, 23andMe's drop followed its Q3 earnings release three days prior, while Beyond Air's decline coincided with its Q3 earnings report.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 9:31 pm

In Thursday's after-market session, several healthcare stocks showed notable movements. Xilio Therapeutics, Sensus Healthcare, Corvus Pharma, SenesTech, Coeptis Therapeutics, and Bright Green were among the gainers, with increases ranging from 4.99% to 10.5%. On the downside, BioXcel Therapeutics, Renalytix, Syra Health, SINTX Techs, NanoString Technologies, and Pro-Dex experienced declines between 8.28% and 42.1%. These movements reflect significant volatility in the healthcare sector, with specific companies showing substantial changes in their stock prices.

Portfolio Pulse from Benzinga Insights

February 08, 2024 | 9:31 pm

Coeptis Therapeutics announced plans to pursue DVX201, its proprietary platform for allogeneic stem cell expansion and directed differentiation, as an antiviral treatment for various respiratory viral infections. This move highlights the company's focus on leveraging its platform to address a broad spectrum of viral challenges.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 12:40 pm

Insiders at OPKO Health, BioCorRx, Coeptis Therapeutics, and Collective Audience have recently purchased shares of their respective companies, signaling confidence in their prospects. OPKO Health's Vice Chairman and CTO acquired 150,000 shares, while BioCorRx's Interim President bought 3,126 shares. Coeptis Therapeutics' CFO purchased 5,000 shares, and Collective Audience's CEO acquired 20,000 shares. These transactions come amidst various company developments, including OPKO Health's private offering, BioCorRx's stock decline, Coeptis Therapeutics' shareholder letter, and Collective Audience's new COO appointment.

Portfolio Pulse from Avi Kapoor

January 18, 2024 | 1:55 pm

In Wednesday's after-market session, several healthcare stocks experienced significant movements. Talphera (TLPH) saw a 10.5% increase, while Virpax Pharmaceuticals (VRPX) dropped by 13%. Other notable gainers include Windtree Therapeutics (WINT), Passage Bio (PASG), Bullfrog AI Hldgs (BFRG), Biora Therapeutics (BIOR), and Coeptis Therapeutics (COEP). On the losing side, Adagene (ADAG), Perspective Therapeutics (CATX), INVO Bioscience (INVO), Compass Therapeutics (CMPX), and Petros Pharma (PTPI) saw declines ranging from 7.57% to 11.26%.

Portfolio Pulse from Benzinga Insights

January 17, 2024 | 9:31 pm

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) announced that research demonstrating the potential of the SNAP-CAR T-cell platform to target multiple antigens, including HER2 and CD20, will be presented at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023). The research suggests that SNAP-CAR can potentially enable the development of T-cell therapies that can be tuned by adaptor dose and targeted toward multiple antigens, potentially avoiding toxicities and relapse due to antigen loss.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:05 pm

Coeptis Therapeutics has expanded its exclusive license agreement with the University of Pittsburgh to include the SNAP-CAR technology platform in natural killer cells. This builds upon the original agreement for SNAP-CAR T-Cell, a platform designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including HER2-expressing cancer.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:37 am

During Thursday's after-market session, several healthcare stocks experienced significant movement. Novo Integrated Sciences (NVOS), OpGen (OPGN), Intelligent Bio Solutions (INBS), Brainstorm Cell (BCLI), BioSig Technologies (BSGM), and Tenax Therapeutics (TENX) saw gains, while Tonix Pharmaceuticals (TNXP), Bionomics (BNOX), Coeptis Therapeutics (COEP), Athersys (ATHX), Nautilus Biotechnology (NAUT), and Avalo Therapeutics (AVTX) experienced losses.

Portfolio Pulse from Benzinga Insights

September 28, 2023 | 9:31 pm

Ladenburg Thalmann analyst Aydin Huseynov has initiated coverage on Coeptis Therapeutics (NASDAQ:COEP) with a Buy rating and a price target of $3.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 11:49 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.